SRC and ovarian carcinoma: Taken an example of SRC (SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase) gene, studies suggest that increased SRC expression results in hypoxic resistance to paclitaxel in ovarian cancer cells, and its inhibition using FV-429 can reverse this resistance [57–59].